Overview Adherence in Topical Treatment of Psoriasis Status: Completed Trial end date: 2017-08-29 Target enrollment: Participant gender: Summary Medical adherence to topical corticosteroid products in psoriasis patients is a main determinant for poor treatment effect. The investigators aim to test if a multifaceted intervention delivered in an app (MyPso QualityCareTM owned by Leo Pharma) for smartphones combined with an Electronic Monitor (EM) (Teslo) can improve medical adherence among psoriasis patients treated with a topical calcipotriol/betamethasone dipropionate foam combination (Cal/BD) (Enstilar©). The study is classified as a phase 4 study, since it is studied if improved use of Enstilar© results in improved treatment outcomes. Link to published study protocol: https://bmcdermatol.biomedcentral.com/articles/10.1186/s12895-018-0071-3 Link to published results from the study: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.16667 Phase: Phase 4 Details Lead Sponsor: Odense University HospitalTreatments: BetamethasoneBetamethasone benzoateBetamethasone sodium phosphateBetamethasone ValerateBetamethasone-17,21-dipropionateCalcipotriene